Skip to main content

Table 3 Univariate and multivariate Cox regression analyses of risk factors for grade ≥ 2 proteinuria after the landmark time point

From: Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study

Variables

Univariate

Multivariate

HR

95% CI

p value

HR

95% CI

p value

Sex, male

0.83

0.49–1.42

0.497

   

Age ≥ 65 years

1.27

0.74–2.17

0.379

   

BMI ≥ 25 mg/kg2

1.51

0.79–2.86

0.212

   

eGFR < 60 mL/min/1.73 m2

1.44

0.78–2.64

0.243

   

Bevacizumab dose of 7.5 mg/kg

1.22

0.71–2.08

0.473

   

Pre-existing hypertension

1.86

1.09–3.19

0.023

1.60

0.92–2.77

0.096

Baseline SBP ≥ 140 mmHg

1.75

0.94–3.27

0.079

   

Baseline DBP ≥ 90 mmHg

1.94

0.92–4.12

0.083

   

Average SBP ≥ 140 mmHg within 3 months

2.33

1.36–4.00

0.002

2.11

1.21–3.67

0.008

Average DBP ≥ 90 mmHg within 3 months

1.79

0.90–3.56

0.097

   
  1. Abbreviations: HR: hazard ratio; CI: confidence interval; BMI: body mass index; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure